Sanyo installs first cell processing workstation in US
To be used to advance stem cell and cell therapy research at the University of Alabama at Birmingham
Sanyo, based in Woodvale, Illinois, says this is the first installation of the CPWS in the US, and the first outside Japan.
The workstation provides the required class-100 aseptic environment in a compact footprint and at a lower cost than a traditional cleanroom, the company says.
The CPWS installed at the university is a positive pressure system, which will aid the school in its research into gene and cellular therapies. A negative pressure CPWS is in development.
The small footprint of the CPWS allows installation into existing or new lab spaces using conventional utilities and minimal site preparation. Offering an efficient operational capacity, the workstation also includes GMP-compliant equipment for aseptic processing and provides user-friendly operation controls.
As well as requiring lower capital costs, the Sanyo CPWS also saves approximately 35% of the operating costs usually required for conventional cleanroom environments.
Sanyo expects the CPWS to make a significant contribution to advancing research in the cell therapy market. Current and future applications of the CPWS include preclinical regenerative cell therapy research for organ and tissue repair and immunotherapies for treating cancer. Additional opportunities for the CPWS include the pharmaceutical bioprocessing market.
The University of Alabama will use the CPWS to manufacture induced pluripotent stem (iPS) cells and gamma-delta T cells for research use. The iPS cells will be studied as a cure for sickle cell anaemia, while Gamma-delta T cells will be studied for treating cancer.
“The CPWS allows seamless preparation of cell and gene therapy products in a totally contained temperature controlled aseptic environment, drastically reducing the risk of microbial contamination,” said Larry Lamb, director of the UAB Cell Therapy Lab, which houses the Sanyo CPWS.
“The technology also has the ability to change over the entire system in 90 minutes allowing for multiple cell products to be produced in a single CPWS.”
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months